Clinical Trial: Mediastinal Grey Zone Lymphoma From the LYSA

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Mediastinal Grey Zone Lymphoma: Clinico-pathological Characteristics and Outcomes of 99 Patients From the LYSA

Brief Summary: Mediastinal grey zone lymphoma, B cell lymphomas with intermediate features between classical Hodgkin lymphoma and primary mediastinal B cell lymphoma, are not well described in the literature. Investigators report the clinical characteristics and outcomes of a large retrospective series of 99 cases centrally reviewed by a panel of hematopathologists, with a consensus established for the diagnosis.

Detailed Summary:
Sponsor: Hospices Civils de Lyon

Current Primary Outcome: EFS in the global population of GZL [ Time Frame: EFS: Event Free Survival from date of randomization until the date of first documented progression, up to 130 months ]

Event-free survival (EFS) was calculated from the date of diagnosis to the date of progression, a change of therapy that was not initially scheduled (radiotherapy, high-dose therapy with autologous stem cell transplantation and other unplanned treatments) or death from any cause.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Hospices Civils de Lyon

Dates:
Date Received: November 4, 2016
Date Started: January 2013
Date Completion:
Last Updated: January 27, 2017
Last Verified: October 2016